VIMTALABS Vimta Labs Q3 FY26 results (Oct–Dec 2025) and concall
Vimta Labs reported a Q3 FY26 revenue of INR 100.5 crores, up 10.2% YoY, driven by pharmaceutical and food testing. However, the quarter experienced a 3.9% QoQ revenue decline due to a lag in clinical research orders and operational challenges, leading to deferred revenues. The company is on track to commercialize biologics services by Q1 FY27 and has doubled capacity in its electronics division, while managing a slight dip in ROCE due to these investments and a one-time exceptional charge of INR 1.6 crores.
You’re reading a preview. Opening the full call uses 1 concall credit.
Sign in to use your monthly call allowance.
What they filed
Q3 FY26: revenue up 10.0%, net profit down 18.2% against the same quarter last year.
| Line item | Q2 FY25 | Q3 FY25 | Q4 FY25 | Q1 FY26 | Q2 FY26 | Q3 FY26 |
|---|---|---|---|---|---|---|
| Revenue | 85 | 90 | 94 | 98 | 102 +20% | 99 +10% |
| EBITDA | 30 | 33 | 33 | 34 | 34 +13% | 34 +3% |
| Net profit | 15 | 22 | 18 | 19 | 20 +33% | 18 −18% |
How to read this
₹ crore, as filed. The percentage beside a figure is the change against the same quarter a year earlier — never the quarter before, which would make every seasonal business look like it collapses and booms each year.
Inve summary of a publicly available earnings call transcript; see how call summaries are prepared. Not investment advice.
